InvestorsHub Logo
Followers 4
Posts 73
Boards Moderated 0
Alias Born 11/02/2020

Re: MayoMobile post# 320925

Tuesday, 07/13/2021 11:55:36 PM

Tuesday, July 13, 2021 11:55:36 PM

Post# of 463404

ALL high dose patients from the phase 2a Alzheimer’s trial improved over SOC regardless of genomic makeup (29% better when combined).



Looking at your added column "% improved over SOC at week 148", the 29% you mention above matches the "All patients" group. Seems like you're implying that "All patients" from the figure are high dose patients, how do we know that? Can't find anywhere that states that.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News